Abstract
Both RAS and transforming growth factor (TGF)-β signaling cascades are central in tumorigenesis and show synergisms depending on tumor stage and tissue context. In this review we focus on the interaction of RAS subeffector proteins with signaling components of the TGF-β family including those of TGF-βs, activins and bone morphogenic proteins. Compelling evidence indicates that RAS signaling is essentially involved in the switch from tumor-suppressive to tumor-promoting functions of the TGF-β family leading to enhanced cancer growth and metastatic dissemination of primary tumors. Thus, the interface of these signaling cascades is considered as a promising target for the development of novel cancer therapeutics. The current pharmacological anti-cancer concepts combating the molecular cooperation between RAS and TGF-β family signaling during carcinoma progression are critically discussed.
Keywords: Activin, BMP, cancer progression, RAS, Smad, targeted therapy, TGF-β.
Current Cancer Drug Targets
Title:The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy
Volume: 10 Issue: 8
Author(s): M. Grusch, M. Petz, T. Metzner, D. Ozturk, D. Schneller and W. Mikulits
Affiliation:
Keywords: Activin, BMP, cancer progression, RAS, Smad, targeted therapy, TGF-β.
Abstract: Both RAS and transforming growth factor (TGF)-β signaling cascades are central in tumorigenesis and show synergisms depending on tumor stage and tissue context. In this review we focus on the interaction of RAS subeffector proteins with signaling components of the TGF-β family including those of TGF-βs, activins and bone morphogenic proteins. Compelling evidence indicates that RAS signaling is essentially involved in the switch from tumor-suppressive to tumor-promoting functions of the TGF-β family leading to enhanced cancer growth and metastatic dissemination of primary tumors. Thus, the interface of these signaling cascades is considered as a promising target for the development of novel cancer therapeutics. The current pharmacological anti-cancer concepts combating the molecular cooperation between RAS and TGF-β family signaling during carcinoma progression are critically discussed.
Export Options
About this article
Cite this article as:
Grusch M., Petz M., Metzner T., Ozturk D., Schneller D. and Mikulits W., The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy, Current Cancer Drug Targets 2010; 10 (8) . https://dx.doi.org/10.2174/156800910793357943
DOI https://dx.doi.org/10.2174/156800910793357943 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dihydrotestosterone Induces Chemo-Resistance of Triple-Negative Breast MDA-MB-231 Cancer Cells Towards Doxorubicin Independent of ABCG2 and miR-328-3p
Current Molecular Pharmacology Marine Actinomycetes-derived Natural Products
Current Topics in Medicinal Chemistry Nanoplatforms for Promoting Osteogenesis in Ovariectomy-Induced Osteoporosis in the Experimental Model
Current Nanomedicine Mast Cells as Target in Cancer Therapy
Current Pharmaceutical Design Editorial (Hot Topic: miRNA in the Pathogenesis and Therapy for Gastrointestinal and Hepatic Cancers)
Current Pharmaceutical Design Ribosomal Proteins and Colorectal Cancer
Current Genomics Effect of Drugs in Cells and Tissues by NMR Spectroscopy
Current Topics in Medicinal Chemistry The ErbB Receptors and their Ligands in Cancer: An Overview
Current Drug Targets The Association of Sleep Disorders, Obesity and Sleep-Related Hypoxia with Cancer
Current Genomics Withdrawal Notice: The Prognostic Value of Prognostic Biomarkers in Esophageal Squamous Cell Carcinoma in Iranian Population
Current Cancer Therapy Reviews Essential Role of Gli Proteins in Glioblastoma Multiforme
Current Protein & Peptide Science Radiation Oncology and Molecular-Targeted Therapy for EGFR and its Signal Transduction Pathways: Molecular Basis and Clinical Application for Improvement of Radiotherapeutic Outcomes
Current Signal Transduction Therapy Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems
Recent Patents on Anti-Cancer Drug Discovery Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design Overview of the Formulations and Analogs in the Taxanes' Story
Current Medicinal Chemistry Blind Snipers: Relevant Off Target Effects of Non-chemotherapeutic Agents in Oncology: Review of the Literature
Reviews on Recent Clinical Trials NSAIDs and Chemoprevention
Current Cancer Drug Targets Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis
Current Genomics Triazole Use in the Nursery: Fluconazole, Voriconazole, Posaconazole, and Ravuconazole
Current Drug Metabolism Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design